GLP‑1 Dose Chart: Wegovy, Ozempic, Zepbound and Mounjaro

On the labeled GLP‑1 dose ladders, Ozempic, Wegovy, Mounjaro and Zepbound each step up after at least 4 weeks on a dose (Ozempic, Wegovy and Zepbound labels). Ozempic runs from 0.25 mg to 2 mg, Wegovy from 0.25 mg to 2.4 mg and then 7.2 mg, and both tirzepatide brands from 2.5 mg to 15 mg. No label converts a semaglutide dose into a tirzepatide dose.

Key facts

• The earliest start for the top dose is week 13 on Ozempic (3 × 4 + 1) and week 21 on Zepbound and Wegovy HD (5 × 4 + 1).
• The pills step up after 30 days or more, so Wegovy tablets reach maintenance on day 91 and Foundayo’s top dose can start on day 151 (Wegovy and Foundayo labels).
• Ozempic and Wegovy both contain semaglutide, and Mounjaro and Zepbound both contain tirzepatide (Ozempic and Zepbound labels, section 11).
• Between the semaglutide tablets, Rybelsus 7 mg pairs with Ozempic tablets 4 mg and Rybelsus 14 mg with 9 mg (tablets label, section 2.3).

GLP‑1 dose ladders in the US labels

The maintenance doses are the ones you can stay on; the others are steps on the way up (Ozempic, Wegovy, Mounjaro and Zepbound labels, section 2).

Ozempic’s steps above 0.5 mg, and every Mounjaro step, are taken only if blood sugar needs more control (Ozempic label, section 2.2; Mounjaro label, section 2.1). With type 2 diabetes and chronic kidney disease, Ozempic’s maintenance dose is 1 mg. Wegovy’s semaglutide titration schedule is set by the week, and maintenance starts in week 17 (Wegovy label, section 2.2). Before that come 0.25 mg in weeks 1 to 4, 0.5 mg in 5 to 8, 1 mg in 9 to 12 and 1.7 mg in 13 to 16.

If every step comes on the first day it is allowed, Ozempic 2 mg starts in week 13, after three 4-week steps. Zepbound 15 mg and Wegovy 7.2 mg start in week 21, after five. For dates instead of week numbers, enter your current dose and the day you started it in the dose titration planner, which holds the Ozempic, Wegovy and tirzepatide ladders. The next step counts from the day you started your current dose, and Pensday keeps the date of every shot you log.

The climb is slow to lower the risk of stomach side effects, the reason each label gives (Zepbound label, section 2.1). Four weeks is also about how long a weekly dose takes to build up. After the fourth dose, tirzepatide is at about 98% of its settled level and semaglutide at about 94%, worked out from each label’s half-life in the GLP‑1 Plotter.

A run of 2 or more missed Wegovy doses sends the climb back to a lower dose (Wegovy label, section 2.4). For a single late shot, the missed-dose window for your brand says whether to take it or skip it.

Your starting dose after a change of brand

No label gives an equivalent between semaglutide and tirzepatide doses, so someone moving from Ozempic or Wegovy starts Zepbound or Mounjaro at 2.5 mg for 4 weeks, like anyone new to it (Zepbound and Mounjaro labels, section 2.1). Switching to Mounjaro after an Ozempic plateau gives the gap between the last and first shots, and the weight results from a chart review. For the move the other way, see switching from Mounjaro to Wegovy.

Ozempic vs Wegovy dose ladders

Ozempic and Wegovy injections are the same drug, semaglutide, so 1 mg of one is 1 mg of the other. Ozempic is licensed for type 2 diabetes and tops out at 2 mg. Wegovy is licensed for weight reduction, heart risk reduction and MASH liver disease, and it adds 1.7 mg and 2.4 mg steps before 7.2 mg (Ozempic and Wegovy labels, sections 1 and 11).

Neither injection’s label gives a conversion to the other. The conversions that do exist on labels run between injections and tablets, and between the two semaglutide tablets. A Wegovy 2.4 mg injection can switch to 25 mg Wegovy tablets, started a week after the last shot (Wegovy label, section 2.5). An Ozempic 0.5 mg injection can switch a week later to Ozempic tablets at 4 or 9 mg, or to Rybelsus at 7 or 14 mg (Rybelsus and Ozempic tablets label, section 2.4).

Rybelsus and Ozempic tablets are both semaglutide, yet their shared label says they "are not substitutable on a mg-to-mg basis" (section 2.1). After the first 30 days on either, you can swap at these doses and start the other tablet the next day (section 2.3, Table 1).

Mounjaro and Zepbound pair up the same way, as two tirzepatide brands in the same six strengths (Mounjaro and Zepbound labels, section 3). In the US, Mounjaro is for type 2 diabetes, and Zepbound for weight reduction and obstructive sleep apnea (Mounjaro and Zepbound labels, section 1).

Wegovy 7.2 mg (Wegovy HD)

Wegovy 7.2 mg is the next step for adults who still need to lose weight after at least 4 weeks on a 2.4 mg dose they tolerate (Wegovy label, section 2.2). FDA approved it on March 19, 2026, as a new dosing regimen, and it comes as a single-dose pen labeled WEGOVY HD (Drugs@FDA, Wegovy; Wegovy label, section 3).

In Study 8, 1,407 adults with obesity and without diabetes took placebo, 2.4 mg or 7.2 mg for 72 weeks, and the placebo group lost 3.9% (Wegovy label, section 14.2, Table 12).

Side effects rose with the dose in Studies 8 and 9, pooled. On placebo, 13% had nausea, 6% vomiting, 1% hair loss and 0% dysesthesia (Wegovy label, section 6.1, Table 4).

Daily GLP‑1 pills

Each pill starts low and steps up after 30 days or more on a dose (Wegovy label, section 2.3; Rybelsus and Ozempic tablets label, section 2.2; Foundayo label, section 2.1). Foundayo is orforglipron, and the other three are semaglutide.

Wegovy tablets move to 25 mg on day 91. Foundayo reaches 17.2 mg on day 151 at the earliest, after five doses of at least 30 days each (5 × 30 + 1). For the 3 mg Rybelsus and 1.5 mg Ozempic tablet starting doses, the label notes that "this dosage is not effective for glycemic control" (Rybelsus and Ozempic tablets label, section 2.2).

FDA approved Wegovy tablets on December 22, 2025 (Drugs@FDA, NDA 218316) and Foundayo on April 1, 2026 (Drugs@FDA, NDA 220934). The Wegovy tablet also comes with its own rules for water and food.

UK dose ladders for Ozempic, Wegovy and Mounjaro

UK doses come from each Summary of Product Characteristics (SmPC), the UK prescribing document, with at least 4 weeks on every step (Ozempic, Wegovy and Mounjaro SmPCs, section 4.2).

In the UK, tirzepatide’s weight-management license sits on Mounjaro. Its SmPC names 5, 10 and 15 mg as the adult maintenance doses, the same three as the US Zepbound label (Mounjaro SmPC, sections 4.1 and 4.2). The UK Wegovy 7.2 mg step is for adults with obesity (Wegovy SmPC, section 4.2), and Ozempic 0.25 mg is "not a maintenance dose" (Ozempic SmPC, section 4.2).

Tools for your dose

The questions that follow a dose change, from a late shot to a new vial strength, each have their own guide or calculator.